Belimumab treatment for adults with systemic lupus erythematosus a review of clinical effectiveness, cost-effectiveness, and guidelines
Systemic lupus erythematosus (SLE) is a chronic, remitting autoimmune disease related to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee did not recommend listing belimumab in public drug formularies in 2012. The recommendation was based...
| Main Authors: | , |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2018, May 23, 2018
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographic references